Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia-Reference-Cited by-同舟云学术

Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia

Published:2022-06 Issue: Volume:Volume 14 Page:1995-2005
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

How Soon Hin,Liam Chong Kin^ORCID,Zainal Abidin Muhammad Adil,Hasbullah Harissa H,Tho Lye Mun,Ho Gwo Fuang^ORCID,Muhamad Nor Ibtisam,Pang Yong Kek^ORCID,Ho Kean Fatt,Thiagarajan Muthukkumaran,Ariffin Roziana,Samsudin Azlina,Omar Azza,Tan Sin Nee,Ong Choo Khoon,Soon Sing Yang,Poh Mau Ern^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference34 articles.

1. Ministry of Health, Malaysia. Malaysia National Cancer Registry report 2012–2016; 2019.

2. Ministry of Health, Malaysia. Malaysian study on cancer survival (MySCan); 2018.

3. Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients

4. P1.08: Updated Analysis of Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?;Translational Lung Cancer Research;2024-02

2. Re‐re‐biopsy? How much tumor is enough in the era of precision oncology?;Asia-Pacific Journal of Clinical Oncology;2023-10-02

3. Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patients;2023-08-10